1) Wang X, Cutting GR. Chronic rhinosinusitis. Adv Otorhinolaryngol 2011;70:114–21.
2) Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in Canadians. Laryngoscope 2003;113(7):1199–205.
3) Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A, et al. Chronic rhinosinusitis in Europe--an underestimated disease. A GA²LEN study. Allergy 2011;66(9):1216–23.
4) Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for U.S. adults: national health interview survey, 2012. Vital Health Stat 10 2014;260:1–161.
5) Kim YS, Kim NH, Seong SY, Kim KR, Lee GB, Kim KS. Prevalence and risk factors of chronic rhinosinusitis in Korea. Am J Rhinol Allergy 2011;25(3):117–21.
6) Chung JH, Lee YJ, Kang TW, Kim KR, Jang DP, Kim IY, et al. Altered quality of life and psychological health (SCL-90-R) in patients with chronic rhinosinusitis with nasal polyps. Ann Otol Rhinol Laryngol 2015;124(8):663–70.
7) Campbell AP, Phillips KM, Hoehle LP, Feng AL, Bergmark RW, Caradonna DS, et al. Depression symptoms and lost productivity in chronic rhinosinusitis. Ann Allergy Asthma Immunol 2017;118(3):286–9.
9) Khan A, Vandeplas G, Huynh TMT, Joish VN, Mannent L, Tomassen P, et al. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology 2019;57(1):32–42.
10) Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol 2016;137(5):1449–56.e4.
11) Zhang Y, Gevaert E, Lou H, Wang X, Zhang L, Bachert C, et al. Chronic rhinosinusitis in Asia. J Allergy Clin Immunol 2017;140(5):1230–9.
12) DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope 2017;127(3):550–5.
13) Alobid I, Antón E, Armengot M, Chao J, Colás C, del Cuvillo A, et al. SEAIC-SEORL. Consensus document on nasal polyposis. POLINA project. J Investig Allergol Clin Immunol 2011;21 Suppl 1:1–58.
14) Rudmik L, Soler ZM. Medical therapies for adult chronic sinusitis: a systematic review. JAMA 2015;314(9):926–39.
15) Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL13 pathway in atopic diseases. Expert Rev Clin Immunol 2017;13(5):425–37.
17) Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol 2021;147(1):29–36.
18) Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol 2016;138(5):1344–53.
19) Kim SJ, Lee KH, Kim SW, Cho JS, Park YK, Shin SY. Changes in histological features of nasal polyps in a Korean population over a 17- year period. Otolaryngol Head Neck Surg 2013;149(3):431–7.
20) Karin J, Tim D, Gabriele H, Cardell LO, Marit W, Claus B. Type 2 inflammatory shift in chronic rhinosinusitis during 2007-2018 in Belgium. Laryngoscope 2021;131(5):E1408–14.
21) Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol 2021;11(3):213–739.
22) Van Zele T, Gevaert P, Holtappels G, Beule A, Wormald PJ, Mayr S, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol 2010;125(5):1069–76.e4.
23) Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 2020;58(Suppl S29):1–464.
24) Mauer Y, Taliercio RM. Managing adult asthma: the 2019 GINA guidelines. Cleve Clin J Med 2020;87(9):569–75.
25) Gan EC, Habib AR, Hathorn I, Javer AR. The efficacy and safety of an office-based polypectomy with a vacuum-powered microdebrider. Int Forum Allergy Rhinol 2013;3(11):890–5.
26) Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol 2015;136(6):1431–40.
27) Bachert C, Zhang N, Cavaliere C, Weiping W, Gevaert E, Krysko O. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2020;145(3):725–39.
28) Kaur D, Hollins F, Woodman L, Yang W, Monk P, May R, et al. Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression. Allergy 2006;61(9):1047–53.
29) Fujieda S, Matsune S, Takeno S, Ohta N, Asako M, Bachert C, et al. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status. Allergy 2021 May 16 [Epub]. Available from:
https://doi.org/10.1111/all.14906.
30) Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016;315(5):469–79.
31) Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019;394(10209):1638–50.
32) Bachert C, Hellings PW, Mullol J, Hamilos DL, Gevaert P, Naclerio RM, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy 2020;75(1):148–57.
33) Bachert C, Hellings PW, Mullol J, Naclerio RM, Chao J, Amin N, et al. Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Pract 2019;7(7):2447–9.e2.
34) Jonstam K, Swanson BN, Mannent LP, Cardell LO, Tian N, Wang Y, et al. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy 2019;74(4):743–52.
35) Takabayashi T, Shigeharu F, Bachert C, Cho SH, Swanson BN, Harel S, et al. Dupilumab reduces blood, urine, and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-52 trial [Abstract]. Proceedings of the 59th Annual Meeting of the Japanese Rhinologic Society. 2020 Oct 10-11; Tokyo, Japan. In: Japanese Rhinologic Society; 2020.
36) Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020;146(3):595–605.
37) Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 2010;48(3):318–24.
38) Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013;131(1):110–6.e1.
39) Bidder T, Sahota J, Rennie C, Lund VJ, Robinson DS, Kariyawasam HH. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study. Rhinology 2018;56(1):42–5.
40) Mostafa BE, Fadel M, Mohammed MA, Hamdi TAH, Askoura AM. Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis. Eur Arch Otorhinolaryngol 2020;277(1):121–8.
41) Hayashi H, Mitsui C, Nakatani E, Fukutomi Y, Kajiwara K, Watai K, et al. Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2016;137(5):1585–7.e4.
42) Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2021;9:1141–53.
43) Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011;128(5):989–95.e1-8.
44) Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol 2017;140(4):1024–31.e14.
45) Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Nasal IL-5 levels determine the response to antiIL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006;118(5):1133–41.
46) Bachert C, Desrosiers M, Gevaert P, Heffler E, Hopkins C, Tversky JR, et al. Efficacy and safety of benralizumab for the treatment of chronic rhinosinusitis with nasal polyps: results from the phase III OSTRO trial. Proceedings of the EAACI Hybrid Congress 2021. 2021 Jul 10-12; Krakow, Republic of Poland. In: EAACI; 2021.
47) Hellings PW, Verhoeven E, Fokkens WJ. State-of-the-art overview on biological treatment for CRSwNP. Rhinology 2021;59(2):151–63.
48) Peters AT, Han JK, Hellings P, Heffler E, Gevaert P, Bachert C, et al. Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 2021;9(6):2461–71.e5.
51) Vannella KM, Ramalingam TR, Borthwick LA, Barron L, Hart KM, Thompson RW, et al. Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine-driven inflammation and fibrosis. Sci Transl Med 2016 8(337):337ra65.ra65.
52) Shin HW, Kim DK, Park MH, Eun KM, Lee M, So D, et al. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol 2015 135(6):1476–85.e7. e7.
54) Hernandez ML, Mills K, Almond M, Todoric K, Aleman MM, Zhang H, et al. IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers. J Allergy Clin Immunol 2015;135(2):379–85.
55) Laidlaw TM, Buchheit KM. Biologics in chronic rhinosinusitis with nasal polyposis. Ann Allergy Asthma Immunol 2020;124(4):326–32.